Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psychiatry Advisor
Among the approved SGAs for MDD, no single medication stands out as the first choice; decision-making is guided by individual patient profiles and side effect considerations.
Psychiatry May 7th 2024
Psych Congress Network
Rejoyn represents a significant advancement in the treatment of major depressive disorder, requiring prescription use and integrating brain-training exercises developed by leading mental health experts.
Epoch Health
Recent clinical case studies highlight that symptoms such as sudden changes in blood sugar levels and depressive episodes without clear psychological causes may be indicative of early-stage pancreatic cancer.
Gastroenterology May 6th 2024
Medical Professionals Reference (MPR)
Explore the potential of Rejoyn™, a digital therapeutic now cleared by the FDA, which has shown to significantly reduce depressive symptoms in adults as an adjunct to traditional outpatient care, without any reported adverse events.
Psychiatry April 9th 2024
British Medical Journal (The BMJ)
The study elucidates the substantial impact of exercise, particularly walking or jogging, yoga, and strength training, in alleviating depressive symptoms, advocating for their inclusion as principal treatments in depression care, reflecting a broadened approach to mental health management.
Psychiatry March 19th 2024
Johns Hopkins Medicine
Johns Hopkins psychiatrists are spearheading a novel educational initiative, ADAP Jr. High, to address the critical gap in middle schoolers’ understanding of anxiety and depression, offering structured lessons and coping strategies to empower young students.
Family Medicine/General Practice March 12th 2024